{"commentary":{"count":39,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":17,"podcast":16,"x_thread":5,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05629585\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT05629585","nct_id":"NCT05629585","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05629585. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Arm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Durvalumab 1120 mg IV Q3W x 9 cycles","label":"Dato-DXd in combination with Durvalumab","type":"EXPERIMENTAL"},{"description":"Arm 2: Dato-DXd 6 mg/kg IV Q3W x 8 cycles","label":"Dato-DXd","type":"EXPERIMENTAL"},{"description":"Arm 3: Capecitabine (1000 or 1250 mg/m2 oral BID on Days 1 to 14, Q3W) for 8 cycles\n\nPembrolizumab\\* (200 mg IV on Day 1, Q3W) for 9 cycles\n\nCapecitabine (1000 or 1250 mg/m2 oral BID on Days 1 to 14, Q3W) for 8 cycles + pembrolizumab\\* (200 mg IV on Day 1, Q3W) for 9 cycles\n\n\\* Only participants who have received prior pembrolizumab in the neoadjuvant setting should receive pembrolizumab as part of their adjuvant therapy on Arm 3.","label":"Investigators Choice Therapy","type":"ACTIVE_COMPARATOR"}],"collaborators":["Daiichi Sankyo","SWOG Clinical Trials Partnerships, LLC"],"completion_date":{"date":"2030-01-30","type":"ESTIMATED"},"conditions":["Breast Cancer"],"enrollment":{"count":1174,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Dato-DXd","type":"DRUG"},{"name":"Durvalumab","type":"DRUG"},{"name":"Capecitabine","type":"DRUG"},{"name":"Pembrolizumab","type":"DRUG"}],"last_update":"2026-06-15","lead_sponsor":"AstraZeneca","official_title":"A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-09-20","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Invasive disease-free survival (iDFS) for Dato-DXd + durvalumab vs. ICT","timeFrame":"From randomisation to date of the event, up to 57 months from first subject in"}],"references":[{"citation":"Bardia A, Pusztai L, Albain K, Ciruelos EM, Im SA, Hershman D, Kalinsky K, Isaacs C, Loirat D, Testa L, Tokunaga E, Wu J, Dry H, Barlow W, Kozarski R, Maxwell M, Harbeck N, Sharma P. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan +/- durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Ther Adv Med Oncol. 2024 Apr 29;16:17588359241248336. doi: 10.1177/17588359241248336. eCollection 2024.","pmid":"38686016","type":"DERIVED"}],"start_date":{"date":"2022-11-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)","url":"https://clinicaltrials.gov/study/NCT05629585"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05629585"}